Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
European Urology Oncology|November 11, 2025
PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical ApplicationsStéphane Oudard, Marc-Olivier Timsit, Denis Maillet, et al.
Bulletin Du Cancer|September 5, 2024
[Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations]Stéphane Oudard, Marc-Olivier Timsit, Denis Maillet, et al.
Cancers|November 13, 2021
First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?Yann-Alexandre Vano, Sylvain Ladoire, Réza Elaidi, et al.
Anti-Cancer Drugs|March 8, 2006
Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancerThierry Petit, Abdellatif Benider, Alejandro Yovine, et al.
The Oncologist|February 1, 2015
Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancerQian Wang-Lopez, Marie-Ange Mouret-Reynier, Aude-Marie Savoye, et al.
Oncology|January 16, 2016
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II StudyHakim Mahammedi, Eloise Planchat, Mélanie Pouget, et al.
Cancer Medicine|March 5, 2021
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancerJudith Passildas-Jahanmohan, Jean-Christophe Eymard, Mélanie Pouget, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO studyThomas Bachelot, Céline Bourgier, Claire Cropet, et al.
BJU International|November 5, 2013
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 studyFlorence Joly, Remy Delva, Loïc Mourey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III TrialKarim Fizazi, Gwénaël Le Teuff, Aude Fléchon, et al.
Pageof 7